**Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention: A Global Expert Consensus Document**

**Emmanouil S. Brilakis, MD, PhD1, Kambis Mashayekhi, MD2, Etsuo Tsuchikane, MD3, Nidal Abu Rafeh, MD4, Khaldoon Alaswad, MD5, Mario Araya, MD6, Alexandre Avran, MD7, Lorenzo Azzalini, MD8, PhD, Avtandil M. Babunashvili, MD9, Bayani Baktash, MD10, Ravinay Bhindi, MD11, Xu Bo, MD12, Nicolas Boudou, MD13, Marouane Boukhris, MD14, Nenad Ž Božinović, MD15, Leszek Bryniarski, MD16, Alexander Bufe, MD17, Chris Buller, MD18, M Nicholas Burke, MD19, Heinz Joachim Büttner, MD20, Pedro Cardoso, MD21, Mauro Carlino, MD22, Evald Christiansen, MD23, Antonio Colombo, MD24, Kevin Croce, MD25, Felix Damas de los Santos, MD26, Tony de Martini, MD27, Jo Dens, MD28, Carlo di Mario, MD29, Kefei Dou, MD30, Mohaned Egred, MD31, Ahmed ElGuindy, MD32, Javier Escaned, MD33, Sergey Furkalo, MD34, Andrea Gagnor, MD35, Alfredo Galassi, MD36, Roberto Garbo, MD37, Junbo Ge, MD38, Pravin Kumar Goel, MD39, Omer Goktekin, MD40, Luca Grancini, MD41, J. Aaron Grantham, MD42, Colm Hanratty, MD43,  Stefan Harb, MD44, Scott A. Harding, MD45, Jose Henriques, MD46, Jonathan Hill, MD47, Farouc Jaffer, MD, PhD48, Yangsoo Jang, MD49, Risto Jussila, MD50, Artis Kalnins, MD51, Arun Kalyanasundaram, MD52, David E. Kandzari, MD53, Hsien-Li Kao, MD54, Dimitri Karmpaliotis, MD, PhD55, Hussien Heshmat Kassem, MD, PhD56, Paul Knaapen, MD57, Ran Kornowski, MD58, Oleg Krestyaninov, MD59, A. V. Ganesh Kumar, MD60, Peep Laanmets, MD61, Pablo Lamelas, MD62, Seung-Whan Lee, MD63, Thierry Lefevre, MD64, Yu Li, MD65, Soo-Teik Lim, MD66, Sidney Lo, MD67, William Lombardi, MD68, Margaret McEntegart, MD69, Muhammad Munawar, MD70, José Andrés Navarro Lecaro, MD71, Hung M Ngo, MD72, William Nicholson, MD73, Göran Olivecrona, MD74, Lucio Padilla, MD75, Marin Postu, MD76, Alexandre Quadros, MD77, Franklin Quesada, MD78, Vithala Surya Prakasa Rao, MD79, Nicolaus Reifart MD80, Meruzhan Saghatelyan, MD81, Ricardo Santiago, MD82, George Sianos, MD, PhD83, Elliot Smith, MD84, James Spratt, MD85, Greg W Stone, MD86, Julian Strange, MD87, Khalid Tammam, MD88, Imre Ungi MD89, Minh Vo, MD90, Vu Hoang Vu, MD91, MD, Simon Walsh, MD92, Gerald Werner, MD93, Jason R. Wollmuth, MD94, Eugene Wu, MD95, R. Michael Wyman, MD96, Masahisa Yamane, MD97, Luiz Ybarra, MD98, Robert W Yeh, MD99, Qi Zhang, MD100, Stephane Rinfret, MD101**

1. Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA;
2. Department of Cardiology and Angiology II University Heart Center Freiburg Bad Krozingen, Bad Krozingen, Germany;

# Toyohashi Heart Center, Aichi, Japan;

1. St. George Hospital University Medical Center, Beirut, Lebanon;
2. Henry Ford Hospital, Detroit, MI, USA;
3. Clínica Alemana and Instituto Nacional del Tórax, Santiago, Chile

# Arnault Tzank Institut St. Laurent Du Var Nice, Saint Laurent du Var, France;

# San Rafaele Scientific Institute, Milan, Italy;

1. Department of Cardiovascular Surgery, Center for Endosurgery and Lithotripsy, Moscow, Russian Federation;
2. Department of Cardiology Mashhad Cardiac Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
3. Department of Cardiology, Royal North Shore Hospital and Kolling Institute, University of Sydney, Sydney, Australia;
4. Fu Wai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases, Beijing, China;
5. Rangueil University Hospital, Toulouse, France;

# Abderrahmen Mami Hospital, Ariana, Tunis;

1. Department of Interventional Cardiology Clinic for Cardiovascular Diseases University Clinical Center Nis, Serbia;

# Jagiellonian University Medical College, Krakow, Poland;

1. Department of Cardiology, Heartcentre Niederrhein, Helios Clinic Krefeld, Krefeld, Germany; Institute for Heart and Circulation Research, University of Cologne, Cologne, Germany; University of Witten/Herdecke, Witten, Germany;
2. St. Michael's Hospital, Toronto, Ontario, Canada;
3. Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA;
4. Department of Cardiology and Angiology II University Heart Center Freiburg Bad Krozingen, Bad Krozingen, Germany;
5. Cardiology Department, Santa Maria University Hospital (CHULN), Lisbon Academic Medical Centre (CAML) and Centro Cardiovascular da Universidade de Lisboa (CCUL), Portugal;
6. San Raffaele Scientific Institute, Milan, Italy;
7. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark;
8. San Raffaele Hospital and Columbus Hospital, Milan, Italy;
9. Brigham and Women's Hospital, Boston, MA, USA;
10. Interventional Cardiology Department. Instituto Nacional de Cardiología. Centro Medico ABC. Medica Sur, Toriello Guerra, Mexico City, Mexico;
11. Advocate Heart Institute, Downers Grove, IL, USA;
12. Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium;
13. Division of Structural Interventional Cardiology, Careggi University Hospital, Florence, Italy;
14. Center for Coronary Heart Disease, State Key Laboratory of Cardiovascular Disease，Fuwai Hospital; National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
15. Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom;
16. Aswan Heart Center, Aswan, Egypt;
17. Hospital Clinico San Carlos and Universidad Complutense de Madrid, Madrid, Spain;
18. Department of Endovascular Surgery and Angiography, National Institute of Surgery and Transplantology of AMS of Ukraine, Kiev, Ukraine;
19. Department of Invasive Cardiology, Maria Vittoria Hospital, Turin, Italy;
20. Department of Medical Sciences and Pediatrics, University of Catania, Catania, Italy;
21. Department of Invasive Cardiology, San Giovanni Bosco Hospital, Turin, Italy;
22. Shanghai Zhongshan Hospital, Shanghai, China;
23. Sanjay Gandhi Post Graduate Institute of Medical Sciences

Lucknow, India;

1. Memorial Hospital, Bezmialem Vakif University, Istanbul, Turkey;
2. Centro Cardiologico Monzino, IRCCS, Milan, Italy;
3. St. Luke's Mid America Heart Institute, Kansas City, MO, USA;
4. Belfast Health and Social Care Trust, Belfast, UK;
5. LKH Graz Süd-West, Standort West, Kardiologie Teaching hospital of the University of Graz, Austria
6. Capital and Coast District Health Board, Wellington Hospital, Wellington, New Zealand;
7. Academic Medical Centre of the University of Amsterdam, Amsterdam, The Netherlands;
8. King’s College Hospital, London, UK;
9. Massachussetts General Hospital, Boston, MA, USA;
10. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea;
11. Kokkola Central Hospital,Tampere University Hospital, Turku University, Finland;
12. Department of Cardiology, Eastern Clinical University Hospital, Riga, Latvia;
13. Fortis Escorts Heart Institute, New Delhi, India
14. Piedmont Heart Institute, Atlanta, GA, USA;
15. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan;
16. Columbia University, New York, NY, USA;
17. Cardiology Department, Kasr Al-Ainy Faculty of Medicine, Cairo University, Egypt and Fujairah Hospital, United Arab Emirates;
18. Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands;
19. Department of Cardiology, Rabin Medical Center, Petach Tikva, "Sackler" School of Medicine, Tel Aviv University, Petach Tikva, Israel;
20. Meshalkin Novosibrisk Research Institute,Novosibirsk, Russia;
21. Departement of Cardiology, Dr LH Hiranandani Hospital, Mumbai, India;
22. North Estonia Medical Center, Tallinn, Estonia;
23. Department of Interventional Cardiology and Endovascular Therapeutics, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina; and Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada;
24. Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea;
25. Institut Cardiovasculaire Paris Sud Hopital prive Jacques Cartier, Massy, France;
26. Department of Cardiology, National Heart Centre Singapore, Singapore;
27. Department of Cardiology, Liverpool Hospital, Sydney, New South Wales,

Australia; The University of New South Wales, Sydney, New South Wales, Australia;

1. University of Washington, Seattle, WA, USA;
2. Golden Jubilee National Hospital, Glasgow, UK;
3. Binawaluya Cardiac Center, Jakarta, Indonesia;
4. Médico Cardiólogo Universitario - Hemodinamista en Hospital de Especialidades Eugenio Espejo y Hospital de los Valles, Argentina;
5. Choray Hospital, Vietnam;
6. WellSpan Health System, York, PA, USA;
7. Skane University Hospital, University of Lund, Lund, Sweeden ;
8. Department of Interventional Cardiology, Instituto Cardiovascular de Buenos Aires, Argentina;
9. Cardiology Department, University of Medicine and Pharmacy “Carol Davila,” Institute of Cardiovascular Diseases “Prof. Dr. C.C. Iliescu,” Sos. Fundeni 258, Sector 2, Bucharest 022328, Romania;
10. Instituto de Cardiologia / Fundação Universitária de Cardiologia - IC/FUC, Porto Alegre, RS – Brazil;
11. CardioHealth, Pereira, Colombia;
12. Hyderguda Apollo, Hyderabad 500 027 India;
13. Department of Cardiology, Main Taunus Heart Institute, Bad Soden, Germany;
14. Nork-Marash Medical Center, Yerevan, Armenia;
15. San Juan, Puerto Rico
16. AHEPA University Hospital, Thessaloniki, Greece;
17. Department of Cardiology, St Bartholomew's Hospital, London, UK;
18. St George's University Hospital NHS Trust, London, UK;
19. Center for Interventional Vascular Therapy, Division of Cardiology, New York-Presbyterian Hospital/Columbia University Medical Center, NY, USA;
20. Department of Cardiology, Bristol Royal Infirmary, UK;
21. Cardiac Center of Excellence, International Medical Center, Jeddah, Saudi Arabia;
22. 2nd Department of Internal Medicine and Cardiology Center, University of Szeged, Szeged, Hungary;
23. Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada;
24. Interventional Cardiology Dept, Heart Center, University Medical Center at Ho Chi Minh City, Vietnam and University of Medicine and Pharmacy,Ho Chi Minh City, Vietnam;
25. Belfast Health and Social Care Trust, Belfast, UK;
26. Medizinische Klinik I Klinikum Darmstadt GmbH, Darmstadt, Germany;
27. Providence Hospiotal, Portland, Oregon
28. Prince of Wales Hospital, Hong Kong;
29. Torrance Memorial Medical Center, Torrance, CA, USA;
30. Saitima St. Luke's International Hospital, Tokyo, Japan;
31. Buenos Aires, Argentina
32. Beth Israel Deaconess Medical Center, Boston, MA, USA;
33. *???????*
34. McGill University Health Centre, McGill University, Montreal, Quebec, Canada

**Disclosures**

1. Emmanouil S. Brilakis, MD, PhD: consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Amgen, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), CSI, Elsevier, GE Healthcare, and Medtronic; research support from Siemens, Regeneron, and Osprey. Shareholder: MHI Ventures. Board of Trustees: Society of Cardiovascular Angiography and Interventions
2. Kambis Mashayekhi , MD:
3. Etsuo Tsuchikane, MD:
4. Nidal Abu Rafeh, MD: CTO Proctor and consultant for Boston Scientific, Abiomed, and Abbott Vascular.
5. Khaldoon Alaswad, MD:
6. Mario Araya, MD: none
7. Alexandre Avran, MD:
8. Lorenzo Azzalini, MD, PhD:
9. Avtandil M. Babunashvili, MD:
10. Bayani Baktash, MD: none
11. Ravinay Bhindi, MD: none
12. Xu Bo: ??
13. Nicolas Boudou, MD,
14. Marouane Boukhris, MD: none
15. Nenad Ž Božinović, MD: none
16. Leszek Bryniarski, MD:
17. Alexander Bufe, MD:
18. Chris Buller, MD:
19. M Nicholas Burke, MD:
20. Heinz Joachim Büttner, MD: none
21. Pedro Cardoso, MD: none
22. Mauro Carlino, MD:
23. Evald Christiansen, MD: none
24. Antonio Colombo, MD:
25. Kevin Croce, MD,
26. Felix Dama de los Santos, MD: speaker and proctor of Boston scientific , Terumo and Abbott
27. Tony de Martini, MD:
28. Jo Dens, MD:
29. Carlo di Mario, MD:
30. Kefei Dou, MD: none
31. Mohaned Egred, MD:
32. Ahmed ElGuindy, MD: proctorship fees from Boston Scientific
33. Javier Escaned, MD:
34. Sergey Furkalo, MD:
35. Andrea Gagnor, MD:
36. Alfredo Galassi, MD:
37. Roberto Garbo, MD:
38. Junbo Ge, MD:
39. Pravin Kumar Goel, MD:
40. Omer Goktekin, MD:
41. Luca Grancini, MD: none
42. J. Aaron Grantham, MD:
43. Colm Hanratty, MD:
44. Stefan Harb, MD:
45. Scott A. Harding, MD:
46. Jose Henriques, MD:
47. Jonathan Hill, MD:
48. Farouc Jaffer, MD, PhD:
49. Yangsoo Jang, MD:
50. Risto Jussila, MD: consulting agreement with EPS Vascular, Boston Scientific inc, Terumo inc
51. Artis Kalnins, MD:
52. Arun Kalyanasundaram,, MD:
53. David E. Kandzari, MD:
54. Hsien-Li Kao, MD:
55. Dimitri Karmpaliotis, MD, PhD:
56. Hussien Heshmat Kassem, MD, PhD: none
57. Paul Knaapen, MD:
58. Ran Kornowski, MD: co-founder of NitiLoop
59. Oleg Krestyaninov, MD:
60. V. Ganesh Kumar, MD: none
61. Peep Laanmets, MD:
62. Pablo Lamelas, MD:
63. Seung-Whan Lee, MD:
64. Thierry Lefevre, MD:
65. Yu Li, MD:
66. Soo-Teik Lim, MD: travel support from Asahi Intecc, Terumo, Kaneka, Boston Scientific, Abbott Vascular
67. Sidney Lo, MD:
68. William Lombardi MD:
69. Margaret McEntegart, MD: none
70. Muhammad Munawar, MD: none
71. José Andrés Navarro Lecaro, MD: none
72. Hung M Ngo, MD: none
73. William Nicholson, MD:
74. Göran Olivecrona, MD: lecture/proctor honoraria: Biotronik, EPS vascular, Biosensors, Edwards Lifesciences
75. Lucio Padilla, MD:
76. Marin Postu:
77. Alexandre Quadros, MD:
78. Franklin Quesada, MD:
79. Vithala Surya Prakasa Rao, MD: none
80. Nicolaus Reifart, MD:
81. Meruzhan Saghatelyan, MD:
82. Ricardo Santiago, MD: proctor and Speaker for Boston Scientific and Speaker for Abbott.
83. George Sianos, MD, PhD:
84. Elliot Smith, MD:
85. James Spratt, MD:
86. Greg W Stone, MD: reports having served as a consultant to: Matrizyme, Miracor, Neovasc, V-wave, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions and Ancora; receiving speaker honoraria from Amaranth and Terumo; holding equity in Ancora, Cagent, Qool Therapeutics, Aria, Caliber, MedFocus family of funds, Biostar family of funds, Applied Therapeutics and SpectraWAVE; serving as a director in SpectraWAVE; and that his employer, Columbia University, receives royalties for sale of the MitraClip from Abbott.

1. Julian Strange, MD:
2. Khalid Tammam, MD:
3. Imre Ungi, MD:
4. Minh Vo, MD:
5. Vu Hoang Vu, MD:
6. Simon Walsh, MD:
7. Gerald Werner, MD:
8. Jason R. Wollmuth, MD:
9. Eugene Wu, MD:
10. R. Michael Wyman, MD: consultant/honoraria from Abbott, Abiomed, Boston Scientific
11. Masahisa Yamane, MD:
12. Luiz Ybarra, MD:
13. Robert W Yeh, MD:
14. Qi Zhang, MD:
15. Stephane Rinfret, MD:

**ABSTRACT**

Outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) has improved due to advancements in equipment and techniques. With global collaboration and knowledge sharing, we have identified 7 common principles that are widely accepted as best practices for CTO-PCI.

1. Symptom improvement is the primary indication for CTO PCI.
2. Dual coronary angiography and in-depth and structured review of the angiogram (and, if available, coronary computed tomography angiography) are key for planning and safely performing CTO-PCI.
3. Use of a microcatheter is essential for optimal guidewire manipulation and exchanges.
4. Antegrade wiring, antegrade dissection and re-entry and the retrograde approach are all necessary crossing strategies. Antegrade wiring is the most common initial technique, while retrograde and antegrade dissection and re-entry are often required for complex CTOs.
5. If the initially selected crossing strategy fails to achieve progress, efficient change to an alternative crossing technique increases the likelihood of eventual PCI success, shortens procedure time, and lowers radiation and contrast use.
6. Specific CTO-PCI expertise and volume and the availability of specialized equipment will increase the likelihood of crossing success and facilitate prevention and management of complications, such as perforation.
7. Meticulous attention to lesion preparation and stenting technique, often requiring intracoronary imaging, is required to ensure optimum stent expansion and minimize the risk of adverse events.

The above principles have been widely adopted by experienced CTO-PCI operators and centers currently achieving high success and acceptable complication rates. Outcomes are less optimal at less experienced centers, highlighting the need for more widespread adoption of the aforementioned seven guiding principles along with the development of additional simple and safe CTO crossing and revascularization strategies through ongoing research, education and training.

**Keywords:** Chronic total occlusion, percutaneous coronary intervention, techniques, outcomes

**CONDENSED ABSTRACT**

We present seven globally-supported key principles for chronic total occlusion (CTO) percutaneous coronary intervention (PCI). First, symptom improvement remains the most common clinical goal. Second, dual coronary angiography and thorough, structured angiogram review are essential. Third, a microcatheter should be used to support the guidewire. Fourth, antegrade wiring, antegrade dissection and re-entry and the retrograde approach are important CTO crossing strategies. Fifth, changes between crossing strategies should be made efficiently if the initial approach fails to achieve progress. Sixth, specific CTO-PCI expertise and equipment, including for complication management, should be available. Seventh, meticulous attention to lesion preparation and stenting technique can help minimize the risk of adverse events.

**Abbreviations and Acronyms**

BASE, balloon-assisted subintimal entry

CCTA, coronary computed tomography angiography

CTO, chronic total occlusion

IVUS, intravascular ultrasound

PCI, percutaneous coronary intervention

Chronic total occlusions (CTOs) are completely occluded arteries with Thrombolysis In Myocardial Infarction (TIMI) 0 flow with an estimated duration of at least 3 months. In recent years the success rates of CTO percutaneous coronary intervention (PCI) have substantially improved, in concert with the maturation and refinement of the key indications, equipment, and techniques for recanalization of occluded coronary arteries. In recent years CTO percutaneous coronary intervention (PCI) has evolved significantly, along with gradual maturation and refinement of the key indications, equipment, and techniques. Global collaboration and sharing of knowledge and techniques have led to the emergence of seven key principles for the performance of CTO-PCI that can help training, clinical practice, and education in this field (**Table 1**).

This document was conceived during CTO-PCI meetings in 2018 (CTO Summit, Multi-Level CTO, and Euro-CTO). An initial document draft was created by a group of CTO-PCI experts from North America, Europe, and Japan. A total of 113 CTO-PCI experts from 56 counties were invited to participate of whom 101 from 50 countries provided comments and approved the final document.

1. **Symptom improvement is the primary indication for CTO-PCI**

Two published randomized-controlled clinical trials 1, 2 and several observational studies 3 have reported symptom improvement after successful CTO-PCI. The EuroCTO (A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions) multicenter trial randomized 407 patients to CTO-PCI vs. optimal medical therapy alone. At 12 months, compared with patients randomized to medical therapy only, patients randomized to CTO-PCI had greater improvement in angina frequency [subscale change difference: 5.23, 95% confidence interval (CI) 1.75-8.71; p=0.003], and quality of life (subscale change difference: 6.62, 95% CI 1.78-11.46; p=0.007), as assessed with the Seattle Angina Questionnaire 1. The single center IMPACTOR-CTO (Impact on Inducible Myocardial Ischemia of PercutAneous Coronary InTervention versus Optimal Medical TheRapy in Patients with Right Coronary Artery Chronic Total Occlusion) trial randomized 94 patients with isolated right coronary artery CTO to CTO-PCI vs optimal medical therapy alone 2. At 12 months, compared with optimal medical therapy, CTO-PCI patients had a significant reduction in ischemic burden and improvement in six-minute walk distance and quality of life as assessed by the short Form-36 Health Survey. Such symptomatic improvement confirms results from multiple observational studies and meta-analyses 4-6. Interpretation of randomized CTO-PCI trials should take into consideration selection bias, since the most symptomatic patients were less likely to be enrolled, as well as crossover between arms. For example, no symptomatic benefits were observed in a third randomized trial, DECISION CTO (Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (presented at the 2017 American College of Cardiology annual meeting). However this study enrolled patients with minimal symptoms in both arms, and crossover rates were high in both treatment arms, randomizing the outcomes toward the null. In addition, no sham-controlled trial has yet been performed, leaving the possibility that some of the observed benefit of CTO-PCI is mediated by the placebo effect. One such trial is underway (SHam-controlled INtErvention to Improve QOL in CTOs - SHINE-CTO; NCT02784418).

In observational studies CTO-PCI relieved regional ischemia 7, and has been associated with improved exercise capacity, increased anaerobic threshold 8, and improvement in depression 9. Viable myocardium supplied by a CTO is a persistently ischemic zone 10, 11. It remains undetermined whether CTO-PCI improves other cardiovascular outcomes, such as left ventricular ejection fraction, risk for arrhythmias, and mortality. Both regional and global left ventricular function improved after successful CTO-PCI in several carefully performed observational studies 12 using paired cardiac magnetic resonance imaging in patients with demonstrable viability or baseline dysfunction 13, but not in two randomized-controlled trials 14, 15. These randomized studies, however, did not examine the presence of viable dysfunctional myocardium at baseline, nor did they assess exercise induced changes in left ventricular function 16. In patients with ischemic cardiomyopathy with reduced ejection fraction, the presence of ischemia and viability in the myocardium supplied by the CTO vessel should be confirmed before considering CTO revascularization. Patients with coronary CTOs who received an implantable cardioverter defibrillator for primary or secondary prevention, had a higher risk for ventricular arrhythmias than patients with non-occlusive coronary artery disease 17, 18 and a higher frequency of recurrent ventricular tachycardia after ablation 19; there been no randomized studies, however, examining whether CTO-PCI reduces the risk for subsequent arrhythmias. In observational studies, patients presenting with ST-segment elevation acute myocardial infarction and a CTO in a non-culprit coronary artery had higher risk for developing cardiogenic shock and higher mortality 20-22.

In a meta-analysis of successful vs. failed CTO-PCI, patients with successful procedures had lower mortality compared with those who had unsuccessful procedures, but findings based on observational studies are subject to bias 4. Observational studies have also demonstrated a lower incidence of major adverse cardiac events with CTO-PCI 23, 24 as compared with medical therapy alone, even among patients with well-developed collateral circulation 25. Although CTO-PCI may improve “hard outcomes”, especially in patients with large ischemic burden (e.g. ischemia of >10% of the myocardium) in whom complete revascularization is achieved 26-28, this hypothesis will require confirmation in well designed, prospective, randomized-controlled clinical trials, such as the ongoing Nordic and Spanish Randomized Trial on the Effect of Revascularization or Optimal Medical Therapy of Chronic Total Coronary Occlusions With Myocardial Ischemia (ISCHEMIA-CTO, [NCT03563417](https://clinicaltrials.gov/show/NCT03563417)) and the NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion (NOBLE-CTO, [NCT03392415](https://clinicaltrials.gov/show/NCT03392415)).

In summary, improving patient symptoms caused by myocardial ischemia (angina, exertional dyspnea, and sometimes fatigue) despite optimal medical therapy remains the only benefit of CTO-PCI that has been demonstrated in randomized-controlled trials and should therefore currently be the primary indication for offering this procedure to patients. The procedural benefit will likely be proportional to symptoms severity, thus an office-based risk-benefit conversation with prospective CTO-PCI patients is strongly encouraged to provide realistic expectations prior to the procedure.

1. **Dual angiography and detailed, structured angiographic review**

The simplest, yet most powerful, technique for improving technical success and reducing complications of CTO-PCI is the performance of high quality, simultaneous dual coronary angiography. The use of two catheters and pressure systems adds little time and cost to the procedure. Dual coronary angiography allows better visualization and understanding of CTO anatomy and is pivotal in estimating the complexity of the lesion and the likelihood of success. Moreover, it improves procedural safety by elucidating the guidewire location during crossing attempts and facilitating management of periprocedural complications, such as perforation. CTO-PCI with a single guide can be done in selected cases with collateral circulation exclusively coming from ipsilateral vessels, for example in CTOs located in a left dominant system 29. In the latter scenario, selective contrast injection in the collateral donor branch through a microcatheter can be performed to reduce contrast administration. Even in the later scenario, use of 2 catheters in the left main will allow for easier guidewire and microcatheter management, especially when using a retrograde approach.

Prior to the procedure, a detailed review and analysis of the angiogram and, if available, coronary computed tomography angiography is essential for creating a primary and secondary procedural plan and assessing the risk / benefit ratio of the procedure. To allow adequate time for procedural planning and preparation ***ad hoc* CTO-PCI should be discouraged** in most cases. CTO-PCI pre-planning can also help minimize contrast and radiation dose, reduce patient and operator fatigue, allow additional evaluation (such as myocardial viability) to be performed, and enable detailed discussion with the patient about all the aspects of the CTO-PCI procedure.

CTO anatomy will dictate the most likely successful and safest crossing strategies. Angiographic review of the CTO anatomy focuses on 4 characteristics: (1) proximal cap morphology; (2) occlusion length, course, and composition (e.g. calcium); (3) quality of the distal vessel; and (4) characteristics of the collateral circulation. Moreover, non-CTO lesions are reviewed, as assessing intermediate left main or other lesions may change clinical decision making leading to alternative revascularization strategies, such as coronary artery bypass graft surgery or pre-CTO-PCI stenting of a donor artery.

**2.1 Proximal cap morphology**

Determining the location and morphology of the proximal cap is critical for selecting an optimal approach to CTO-PCI. Attempts to cross ambiguous proximal caps may lead to perforation. Additional angiographic projections using dual injection, selective contrast injection through a microcatheter located near the proximal cap, use of intravascular ultrasound (IVUS) 30, or pre-procedural or real-time coronary computed tomography angiography co-registration 31 may help clarify the location of the proximal cap 32. If proximal cap ambiguity cannot be resolved, a retrograde approach is often recommended as primary strategy.

When operators are facile with the antegrade and dissection reentry technique and have access to proper equipment for reentry, subintimal techniques such as balloon-assisted subintimal entry (BASE, i.e. inflation of a balloon proximal to the occlusion to cause a dissection, followed by subintimal guidewire entry and subintimal crossing of the occlusion) may be used 33.

* 1. **Lesion length, course, and composition**

Lesion length is often overestimated with antegrade only injections due to under filling and poor opacification of the distal vessel, from competing antegrade and retrograde coronary flow, leaving uncertainty about the location and morphology of the distal cap. Dual injection allows more accurate estimation of CTO length and the distal cap anatomy. Severe calcification and tortuosity of the occluded segment can hinder CTO crossing and increase the likelihood of subadventitial guidewire entry. Advancing a knuckled (J-shaped) guidewire or changing to the retrograde approach is often preferred when the vessel course is unclear or highly tortuous 34, as such a wire shape allows advancement within the vessel architecture with low risk of perforation 35.

* 1. **Distal vessel**

A distal vessel that fills well, does not have significant disease and is free from major branches facilitates CTO recanalization. Conversely, small, diffusely diseased distal vessels are more challenging to recanalize, especially following subintimal guidewire entry. In some cases, however, distal vessels are small due to hypoperfusion, leading to negative remodeling and will increase in size after recanalization 36. Distal CTO caps in native coronary artery CTOs are more likely to be calcified and resistant to guidewire penetration in prior CABG patients 37. Moreover, distal vessel calcification may hinder wire re-entry in case of subintimal guidewire entry. The presence of a bifurcation at the distal cap (as well as at the proximal cap or within the occluded segment) may hinder antegrade wiring of the main branch and also increases the likelihood of side branch loss, favoring use of the retrograde approach.

* 1. **Collateral circulation**

Evaluation of the collateral circulation is critical for determining the feasibility of the retrograde approach 38. High quality angiography (ideally obtained in apnea and without panning) allowing complete opacification of collateral vessels and obtained in optimal angiographic projections, should therefore be encouraged as part of routine diagnostic studies when a CTO is found. Retrograde access to the distal vessel can be obtained via septal collaterals, epicardial collaterals, or (patent or occluded) coronary bypass grafts. When assessing collateral channels it is important to consider size, tortuosity, angle of entry to and exit from the collateral, and distance from the collateral exit to the distal cap. The most important predictor of successful guidewire and device crossing is lack of tortuosity, followed by size 39. The size of the collaterals is often assessed using the Werner classification 10. In addition, crossing invisible septal collateral channels is often possible with the surfing technique, letting the wire find the path of least resistance 40. It is helpful to carefully study previous angiograms for multiple potential collateral pathways, as the predominant collateral may change over time prior to the procedure or during the course of PCI (“shifting collaterals”). Previously visualized collaterals that disappear at the time of the procedure may still be crossable. Whenever required and after ensuring adequate backflow to prevent barotrauma, selective contrast tip injections through the microcatheter can be safely performed to outline collateral anatomy. Patent bypass grafts represent an ideal retrograde conduit due to the absence of side branches, predictable course and large caliber. Even occluded grafts can be used as retrograde pathways. Septal collaterals are typically safer and easier to navigate using very soft tip and polymer-jacketed guidewires compared with epicardial collaterals 41, 42. In contrast to epicardial collaterals, septal collaterals can be safely dilated with small balloons to facilitate microcatheter or device crossing if required. The donor vessel proximal to the collateral origin, as well as collateral dominance (ie. presence of a single large visible collateral), should also be assessed during retrograde procedures to determine the risk for ischemia during retrograde crossing attempts. Careful review of collaterals prior to the procedure can reduce contrast and radiation dose as well as the duration of the procedure. In cases where the collateral anatomy is unclear or ambiguous, it can be helpful to perform selective injection of contrast into the collateral through the center lumen of a microcatheter placed into the collateral using a 2-3 cc syringe. Furthermore, in cases where unfavorable non-interventional epicardial collaterals provide the dominant blood flow to the CTO, it can be useful to balloon occlude the epicardial collateral for 2-4 minutes to see if more favorable interventional collaterals can be recruited and identified for attempts at retrograde crossing.

* 1. **CTO scores**

Angiographic and clinical characteristics, such as prior CTO-PCI failure 43 and prior CABG 44, have been combined to create scores for estimating the difficulty and hazard of a specific CTO-PCI in various patient populations. The first and most commonly used CTO-PCI score is the J-CTO score (Multicenter CTO Registry of Japan), developed to estimate the likelihood of successful antegrade guidewire crossing within 30 minutes based on 5 criteria (at least 1 bend of >45° in the CTO entry or CTO body, occlusion length >20 mm, calcification, blunt proximal stump, and previously failed attempt) 45. The J-CTO score has been validated in other CTO-PCI cohorts 43 and is also associated with 1-year clinical outcomes 46. Other scores include the PROGRESS-CTO score 47, the RECHARGE (**RE**gistry of **C**rossboss and **H**ybrid Procedures in Fr**A**nce, the Nethe**R**lands, Bel**G**ium and Unit**E**d Kingdom) registry score 48, the CL-score [**C**linical and **L**esion related score) 49, the ORA (**o**stial location, collateral filling of **R**entrop <2, **a**ge over 75) score 50, the Ellis et al. score 51, the weighted angiographic scoring model (W-CTO score) 52, and the CASTLE (**C**ABG history, **A**ge (≥70yrs), **S**tump anatomy (blunt or invisible), **T**ortuosity degree (severe or unseen), **L**ength of occlusion (≥20 mm) and **E**xtent of calcification (severe)] score 53. There are also CCTA-based scores, such as the CT-RECTOR multicenter registry (Computed Tomography Registry of Chronic Total Occlusion Revascularization) score 54 and the Korean Multicenter CTO CT Registry Score 55. Various scores have similar predictive capacity for technical success and are more accurate in antegrade-only cases 56. Risk of complications can also be predicted using the Progress-CTO complications score which uses 3 variables (age ≥ 65 years, lesion length > 23 mm, and use of the retrograde approach) to stratify patients for the risk of periprocedural complications 57. Each score is generally only applicable to the population from which it was derived and validated. Calculating one or more scores can promote detailed review of the angiogram and facilitate decision making. For example, medical therapy may be preferred over CTO-PCI in mildly symptomatic patients with highly complex occlusions. Complex CTOs (such as those with J-CTO score ≥2) are more likely to require dissection re-entry and retrograde crossing techniques and should be performed by experienced operators.

1. **Use of a microcatheter for guidewire manipulation**

A microcatheter should be routinely used for supporting the coronary guidewire and allowing rapid guidewire switching during both antegrade and retrograde wire manipulation. Microcatheters improve the precision of both rotational and longitudinal guidewire movements both in fluid (blood filled vessels) and in tissue (the occlusion itself) and allow the penetration force of the wire to be dynamically altered by changing the distance between the tip of the guidewire and the microcatheter, with microcatheters becoming stiffer when the microcatheter is positioned close to the guidewire tip. Microcatheters also allow rapid guidewire tip reshaping or exchange, while preserving prior guidewire crossing or advancement achieved. Microcatheters inherently dilate retrograde collateral channels and protect them from wire-induced trauma. Microcatheters can also be used to deliver contrast either for visualization or to accomplish the Carlino technique (intra-lesional injection of 1-2 mL of contrast to elucidate microcatheter position and/or facilitate crossing), especially in wire resistant lesions 58. A microcatheter is preferred over an over-the-wire balloon as it has a marker at the distal tip, providing adequate fluoroscopic feedback of its actual position and also provides greater freedom of advancement with a lower profile and better wire to lumen internal diameter ratio. Also, unlike over-the-wire plastic balloon catheter shafts that are prone to kinking, nearly all contemporary coronary microcatheters incorporate a kink-resistant metallic braid.

Several microcatheters are currently available. Microcatheters utilized in CTO-PCI can be broadly classified into 4 categories: (a) larger microcatheters, often with threaded external surfaces, that provide stronger support; (b) lower profile, flexible microcatheters optimized for advancing through microchannels and collaterals; (c) dual lumen microcatheters that can facilitate parallel wiring and wiring of bifurcated lesions; and (d) angulated microcatheters that can facilitate wire advancement around acute angles.

Similar to guidewires, microcatheter selection depends on the CTO angiographic characteristics, local availability, and expertise. In addition to using a microcatheter, obtaining coaxial guide position and strong guide support can significantly facilitate CTO crossing.

1. **CTO crossing strategies**

There are 4 CTO crossing strategies, classified according to wiring direction (antegrade and retrograde) and whether or not the subintimal space is utilized (wiring vs. dissection and re-entry).

**4.1 Antegrade wiring**

Antegrade wiring (also called antegrade wire escalation) is the most widely used CTO crossing technique 30, 59-61. Various guidewires are advanced in the antegrade direction (original direction of blood flow). Guidewire choice depends on CTO characteristics. If there is a tapered proximal cap or a functional occlusion with a visible channel, a polymer-jacketed, low penetration force, tapered guidewire is used initially, with subsequent escalation to intermediate and high penetration force guidewires, as required. If there is a blunt proximal cap, antegrade wiring is usually started with an intermediate penetration force polymer-jacketed guidewire, or a composite core guidewire. Stiff, high penetration force guidewires may be required in highly resistant proximal caps or when areas of resistance are encountered within the body of the occlusion. After proximal cap crossing, however, de-escalation to less penetrating guidewires should be done for navigation through the CTO segment.

Contralateral injection and orthogonal angiographic projections are critical for determining guidewire position during crossing attempts. If the guidewire enters into the distal true lumen, the microcatheter is then advanced into the distal true lumen and the dedicated CTO guidewire is then exchanged for a workhorse guidewire through the microcatheter to minimize the risk for distal vessel injury and perforation during balloon angioplasty and stenting (wire de-escalation). If the guidewire exits the vessel structure it should be withdrawn and re-directed **without** advancing microcatheters, balloons, or stents over it. If the guidewire enters the subintimal space it can be redirected, but if this maneuver fails, the wire can be left in place to aid directing a second guidewire into the distal true lumen (parallel wire technique), which can be assisted by a dual lumen microcatheter, or facilitated by the use of IVUS 30. Alternatively, antegrade dissection/re-entry techniques can be used to re-enter into the distal true lumen, as described below. Subintimal guidewire advancement distal to the distal cap should be avoided as it can lead to hematoma formation, causing luminal compression and reducing the likelihood of success. Antegrade vessel re-entry can be guided by IVUS, although this approach requires expertise and may by hindered by limited wire maneuverability in the presence of the subintimal IVUS catheter.

* 1. **Antegrade dissection and re-entry**

Antegrade dissection and re-entry involves entering the subintimal space, followed by subintimal crossing of the CTO with subsequent re-entry into the distal true lumen. Antegrade dissection and re-entry may be intentional or un-intentional during antegrade wiring attempts. The first dissection re-entry technique developed was named STAR (**S**ubintimal **T**racking **A**nd **R**e-Entry) and used inadvertent, poorly controllable re-entry into the distal lumen 62. This frequently necessitated stenting long coronary segments with occlusion of numerous side branches, with extensive vascular injury with high rates of in-stent restenosis and re-occlusion. As such, the STAR technique has evolved to a bailout strategy without stent implantation after ballooning, in preparation for a repeat CTO-PCI attempt (subintimal plaque modification, also termed an “investment” procedure) 62-65. The development of limited dissection/re-entry techniques (using dedicated re-entry systems 66, 67 or wire based strategies 68, 69) was an important advance, as they minimize vascular injury, limit the length of dissection and subsequent stent length, and increase the likelihood of side branch preservation 35, 66, 70. Such approaches have been associated with favorable clinical outcomes 70-74.

* 1. **The retrograde approach**

The retrograde technique differs from the antegrade approach in that the occlusion is approached from the distal vessel with guidewire advancement against the original direction of blood flow 75. A guidewire is advanced into the artery distal to the occlusion through a collateral channel or through a bypass graft, followed by placement of a microcatheter at the distal CTO cap. Retrograde CTO crossing is then attempted either with retrograde wiring [usually for short occlusions, especially when the distal cap is tapered 37] or using retrograde dissection/re-entry techniques.

The most commonly used retrograde crossing technique is reverse controlled antegrade and retrograde tracking (reverse CART), in which a balloon is inflated over the antegrade guidewire, followed by retrograde guidewire advancement into the space created by the antegrade balloon. In challenging reverse CART cases, intravascular ultrasound can clarify the mechanism of failure and increase the likelihood of success 76. Guide catheter extensions can also facilitate reverse CART 77.

* 1. **Crossing strategy selection**

Selecting the initial and subsequent crossing strategies depends on the CTO lesion characteristics and local equipment availability and expertise.

Several algorithms have been developed to facilitate crossing strategy selection, such as the hybrid 78 and Asia Pacific 34 algorithm. Antegrade crossing is generally preferred over retrograde crossing as the initial crossing strategy, given the higher risk of complications with the retrograde approach 59-61 and need for antegrade lesion preparation even when the retrograde approach is eventually required. Some retrograde CTO-PCI complications, however, are caused by antegrade crossing attempts. The retrograde approach remains critical for achieving high success rates, especially in more complex CTOs 61, 79, and has been associated with favorable long-term outcomes 80.

CTOs with proximal cap ambiguity and flush aorto-ostial CTOs are often approached with a primary retrograde approach. Alternatively, they can be approached in the antegrade direction, especially when no collateral or graft can be used by using: (a) using intravascular ultrasound or pre-procedural computed tomography coronary angiography for determining the location of the proximal cap and vessel course 31, 34, 81, or (b) techniques to facilitate entry into the subintimal space proximal to the occlusion 33.

1. **Change of crossing strategy**

Flexibility is important for the success, safety, and efficiency of CTO-PCI. If the initial or subsequent crossing strategy fails to achieve progress, small changes (such as modifying the guidewire tip angulation or changing guidewire) or more significant changes (such as converting from an antegrade to a retrograde approach) should be made, based on pre-procedural planning. It is important to avoid getting “stuck in a failure mode”, in which excessive time, radiation and contrast are expended with little or no progress being made while repeatedly attempting the same technique, as this will preclude the use of alternative strategies and increase the risk of complications.

Similar to selection of the initial crossing strategy, the timing and choice of subsequent crossing strategies depends on lesion characteristics, challenges encountered with the original technique, and equipment availability and expertise, and can be guided by existing crossing algorithms 34, 78. Only approximately 50-60% of CTOs are successfully crossed with the initial strategy 29, 59, 60. Changing strategies can help maximize the likelihood of eventual success and limit contrast volume and radiation dose.

Reasons to stop a CTO-PCI attempt include occurrence of a complication, high radiation dose (usually >5 Gray air kerma dose in the absence of lesion crossing or substantial progress), large contrast volume administration, exhaustion of crossing options, or patient or physician fatigue. As with all interventions, careful assessment of individual risk vs. benefit should guide decision-making and choice of strategy during different stages of the procedure. On many occasions, it may be best to fail rather than pursue highly aggressive strategies that may lead to serious complications 59.

1. **Equipment and physician team expertise**

CTO-PCI should be performed within dedicated programs that promote continual training and rigorous monitoring of outcomes.{Karmpaliotis, 2013 #3586} Higher CTO PCI volume has been associated with higher success rates.{Brilakis, 2015 #4752}{Ellis, 2017 #6280}{Kinnaird, 2018 #6610}

The performance of CTO-PCI by a skilled physician and team is especially important to minimize and manage procedural complications. CTO-PCI carries increased risk of complications compared with non-CTO-PCI 82, especially perforation, which occurred in all fatal events in a contemporary multicenter registry 3. Across multiple contemporary registries, tamponade occurred in 0.4 to 1.3% of cases **(Table 2).** Guidewire perforation within the CTO segment infrequently results in clinically significant pericardial bleeding. In contrast, balloon or microcatheter advancement outside the vessel architecture is significantly more likely to result in intra-myocardial or pericardial bleeding, leading to tamponade, or loculated hematoma, often called “dry” tamponade. Additional CTO-PCI adverse events include access site complications, donor vessel injury, arrhythmias, stroke, contrast induced nephropathy, radiation dermatitis, emergency coronary bypass graft surgery, and death 83. The average complication risk is approximately 3%, but varies widely between studies (**Table 2**) and is increased with greater lesion complexity 3, 59-61, 84, 85.

Dual injection minimizes the risk for perforation by helping determine guidewire position. Placement of a “safety” guidewire in the CTO donor vessel can facilitate treatment if donor vessel injury occurs. Maintaining an activated clotting time (ACT) of ≥300 seconds reduces the risk of donor vessel thrombosis; the ACT should be checked at least every 30 minutes during the procedure. In case of perforation, covered stents and coils should be available to treat large vessel and distal vessel perforations, respectively. Pre-procedural operator training in proper use of these devices will ensure efficient use in the emergency setting. In case of epicardial collateral perforation 42, 86 embolization from both directions (using coils, thrombin, fat, etc) is often needed to achieve sealing 87. Special attention should be given to patients with prior coronary bypass graft surgery, as perforation can result in life-threatening, difficult to access, loculated hematomas 88, 89.

Meticulous attention should also be paid to minimizing radiation dose and the risk for radiation skin injury. This can be achieved by using low-frame rate fluoroscopy and the “fluoroscopy store” function for documenting balloon and stent inflation instead of cine-angiography, using collimation, minimizing the distance of the image receptor from the patient, and intermittently changing the position of the image receptor during the procedure. Similarly, contrast administration should be minimized through meticulous pre-procedural planning and use of contrast-sparing devices to reduce the risk for contrast nephropathy.

1. **Optimal stent deployment**

CTOs often have large plaque burden and often contain calcific segments that may offer resistance to optimal stent expansion absent good preparation. As such, efforts should be made to predilate the segment with properly sized balloons, and use of atherectomy may be required. It is essential to achieve full lesion expansion before stent implantation. CTO-PCI often involves placement of multiple stents in vessels that are calcified, diffusely diseased and negatively remodeled. Given the often arduous and lengthy attempts required for CTO crossing, less attention may be given to stent optimization (maximal stent expansion and optimal inflow and outflow), potentially resulting in higher rates of restenosis and stent thrombosis. Intravascular imaging can facilitate assessment of vessel size and calcification prior to stenting and the adequacy of stent expansion, apposition and lesion coverage, to reduce the risk for subsequent adverse events 90-93. Moderate diffuse disease distal to the CTO often does not require treatment, as the distal vessel often enlarges over time after restoring vessel patency 94.

Routine high-pressure post-dilation 90, 91 of adequate duration may help optimize acute stent expansion and improve long-term outcomes. However, caution should be used when ballooning heavily calcified coronary segments or areas of subintimal crossing, as they may carry increased risk for perforation. Use of intravascular imaging can reduce the likelihood of stent oversizing and the risk for perforation.

**Conclusions**

Extensive interactions and collaboration across the world have led to the advancements in CTO-PCI that are summarized in the seven key principles outlined in this global expert consensus document. These principles can guide training of new CTO-PCI operators and program development and facilitate further improvement in the success, safety, and clinical outcomes of CTO-PCI.

**References**

1. Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR, Louvard Y and investigators Et. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. *Eur Heart J*. 2018.

2. Obedinskiy AA, Kretov EI, Boukhris M, Kurbatov VP, Osiev AG, Ibn Elhadj Z, Obedinskaya NR, Kasbaoui S, Grazhdankin IO, Prokhorikhin AA, Zubarev DD, Biryukov A, Pokushalov E, Galassi AR and Baystrukov VI. The IMPACTOR-CTO Trial. *JACC Cardiovascular interventions*. 2018;11:1309-1311.

3. Sapontis J, Salisbury AC, Yeh RW, Cohen DJ, Hirai T, Lombardi W, McCabe JM, Karmpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Thompson CR, Marso SP, Nugent K, Gosch K, Spertus JA and Grantham JA. Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). *JACC Cardiovascular interventions*. 2017;10:1523-1534.

4. Christakopoulos GE, Christopoulos G, Carlino M, Jeroudi OM, Roesle M, Rangan BV, Abdullah S, Grodin J, Kumbhani DJ, Vo M, Luna M, Alaswad K, Karmpaliotis D, Rinfret S, Garcia S, Banerjee S and Brilakis ES. Meta-analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total occlusions. *Am J Cardiol*. 2015;115:1367-75.

5. Joyal D, Afilalo J and Rinfret S. Effectiveness of recanalization of chronic total occlusions: a systematic review and meta-analysis. *Am Heart J*. 2010;160:179-87.

6. Ybarra LF, Dautov R, Gibrat C, Dandona S and Rinfret S. Midterm Angina-Related Quality of Life Benefits After Percutaneous Coronary Intervention of Chronic Total Occlusions. *Can J Cardiol*. 2017;33:1668-1674.

7. Sachdeva R, Agrawal M, Flynn SE, Werner GS and Uretsky BF. Reversal of ischemia of donor artery myocardium after recanalization of a chronic total occlusion. *Catheter Cardiovasc Interv*. 2013;82:E453-8.

8. Mashayekhi K, Neuser H, Kraus A, Zimmer M, Dalibor J, Akin I, Werner G, Aurel T, Neumann FJ and Behnes M. Successful Percutaneous Coronary Intervention Improves Cardiopulmonary Exercise Capacity in Patients With Chronic Total Occlusions. *J Am Coll Cardiol*. 2017;69:1095-1096.

9. Bruckel JT, Jaffer FA, O'Brien C, Stone L, Pomerantsev E and Yeh RW. Angina Severity, Depression, and Response to Percutaneous Revascularization in Patients With Chronic Total Occlusion of Coronary Arteries. *J Invasive Cardiol*. 2016;28:44-51.

10. Werner GS, Ferrari M, Heinke S, Kuethe F, Surber R, Richartz BM and Figulla HR. Angiographic assessment of collateral connections in comparison with invasively determined collateral function in chronic coronary occlusions. *Circulation*. 2003;107:1972-7.

11. Sachdeva R, Agrawal M, Flynn SE, Werner GS and Uretsky BF. The myocardium supplied by a chronic total occlusion is a persistently ischemic zone. *Catheter Cardiovasc Interv*. 2014;83:9-16.

12. Galassi AR, Boukhris M, Toma A, Elhadj Z, Laroussi L, Gaemperli O, Behnes M, Akin I, Luscher TF, Neumann FJ and Mashayekhi K. Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients With Low Left Ventricular Ejection Fraction. *JACC Cardiovascular interventions*. 2017;10:2158-2170.

13. Megaly M, Saad M, Tajti P, Burke MN, Chavez I, Gossl M, Lips D, Mooney M, Poulose A, Sorajja P, Traverse J, Wang Y, Kohl LP, Bradley SM and Brilakis ES. Meta-analysis of the impact of successful chronic total occlusion percutaneous coronary intervention on left ventricular systolic function and reverse remodeling. *J Interv Cardiol*. 2018.

14. Henriques JP, Hoebers LP, Ramunddal T, Laanmets P, Eriksen E, Bax M, Ioanes D, Suttorp MJ, Strauss BH, Barbato E, Nijveldt R, van Rossum AC, Marques KM, Elias J, van Dongen IM, Claessen BE, Tijssen JG, van der Schaaf RJ and Investigators ET. Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial. *J Am Coll Cardiol*. 2016;68:1622-1632.

15. Mashayekhi K, Nuhrenberg TG, Toma A, Gick M, Ferenc M, Hochholzer W, Comberg T, Rothe J, Valina CM, Loffelhardt N, Ayoub M, Zhao M, Bremicker J, Jander N, Minners J, Ruile P, Behnes M, Akin I, Schaufele T, Neumann FJ and Buttner HJ. A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion: The REVASC Trial. *JACC Cardiovascular interventions*. 2018;11:1982-1991.

16. Kirschbaum SW, Baks T, van den Ent M, Sianos G, Krestin GP, Serruys PW, de Feyter PJ and van Geuns RJ. Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions. *Am J Cardiol*. 2008;101:179-85.

17. Nombela-Franco L, Mitroi CD, Fernandez-Lozano I, Garcia-Touchard A, Toquero J, Castro-Urda V, Fernandez-Diaz JA, Perez-Pereira E, Beltran-Correas P, Segovia J, Werner GS, Javier G and Luis AP. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study). *Circ Arrhythm Electrophysiol*. 2012;5:147-54.

18. Nombela-Franco L, Iannaccone M, Anguera I, Amat-Santos IJ, Sanchez-Garcia M, Bautista D, Calvelo MN, Di Marco A, Moretti C, Pozzi R, Scaglione M, Canadas V, Sandin-Fuentes M, Arenal A, Bagur R, Perez-Castellano N, Fernandez-Perez C, Gaita F, Macaya C, Escaned J and Fernandez-Lozano I. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis. *JACC Cardiovascular interventions*. 2017;10:879-888.

19. Di Marco A, Paglino G, Oloriz T, Maccabelli G, Baratto F, Vergara P, Bisceglia C, Anguera I, Sala S, Sora N, Dallaglio P, Marzi A, Trevisi N, Mazzone P and Della Bella P. Impact of a chronic total occlusion in an infarct-related artery on the long-term outcome of ventricular tachycardia ablation. *J Cardiovasc Electrophysiol*. 2015;26:532-9.

20. Claessen BE, Hoebers LP, van der Schaaf RJ, Kikkert WJ, Engstrom AE, Vis MM, Baan J, Jr., Koch KT, Meuwissen M, van Royen N, de Winter RJ, Tijssen JG, Piek JJ and Henriques JP. Prevalence and impact of a chronic total occlusion in a non-infarct-related artery on long-term mortality in diabetic patients with ST elevation myocardial infarction. *Heart*. 2010;96:1968-72.

21. Claessen BE, Dangas GD, Weisz G, Witzenbichler B, Guagliumi G, Mockel M, Brener SJ, Xu K, Henriques JP, Mehran R and Stone GW. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. *Eur Heart J*. 2012;33:768-75.

22. van der Schaaf RJ, Claessen BE, Vis MM, Hoebers LP, Koch KT, Baan J, Jr., Meuwissen M, Engstrom AE, Kikkert WJ, Tijssen JG, de Winter RJ, Piek JJ and Henriques JP. Effect of multivessel coronary disease with or without concurrent chronic total occlusion on one-year mortality in patients treated with primary percutaneous coronary intervention for cardiogenic shock. *Am J Cardiol*. 2010;105:955-9.

23. Tomasello SD, Boukhris M, Giubilato S, Marza F, Garbo R, Contegiacomo G, Marzocchi A, Niccoli G, Gagnor A, Varbella F, Desideri A, Rubartelli P, Cioppa A, Baralis G and Galassi AR. Management strategies in patients affected by chronic total occlusions: results from the Italian Registry of Chronic Total Occlusions. *Eur Heart J*. 2015;36:3189-98.

24. Yang JH, Kim BS, Jang WJ, Ahn J, Park TK, Song YB, Hahn JY, Choi JH, Lee SH, Gwon HC and Choi SH. Optimal Medical Therapy vs. Percutaneous Coronary Intervention for Patients With Coronary Chronic Total Occlusion - A Propensity-Matched Analysis. *Circ J*. 2016;80:211-7.

25. Jang WJ, Yang JH, Choi SH, Song YB, Hahn JY, Choi JH, Kim WS, Lee YT and Gwon HC. Long-term survival benefit of revascularization compared with medical therapy in patients with coronary chronic total occlusion and well-developed collateral circulation. *JACC Cardiovascular interventions*. 2015;8:271-9.

26. Garcia S, Sandoval Y, Roukoz H, Adabag S, Canoniero M, Yannopoulos D and Brilakis ES. Outcomes after complete versus incomplete revascularization of patients with multivessel coronary artery disease: a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. *J Am Coll Cardiol*. 2013;62:1421-31.

27. Farooq V, Serruys PW, Garcia-Garcia HM, Zhang Y, Bourantas CV, Holmes DR, Mack M, Feldman T, Morice MC, Stahle E, James S, Colombo A, Diletti R, Papafaklis MI, de Vries T, Morel MA, van Es GA, Mohr FW, Dawkins KD, Kappetein AP, Sianos G and Boersma E. The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. *J Am Coll Cardiol*. 2013;61:282-94.

28. Goel PK, Khanna R, Pandey CM and Ashfaq F. Long-term outcomes post chronic total occlusion intervention-implications of completeness of revascularization. *J Interv Cardiol*. 2018;31:293-301.

29. Azzalini L, Agostoni P, Benincasa S, Knaapen P, Schumacher SP, Dens J, Maeremans J, Kraaijeveld AO, Timmers L, Behnes M, Akin I, Toma A, Neumann FJ, Colombo A, Carlino M and Mashayekhi K. Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention Through Ipsilateral Collateral Channels: A Multicenter Registry. *JACC Cardiovascular interventions*. 2017;10:1489-1497.

30. Suzuki Y, Tsuchikane E, Katoh O, Muramatsu T, Muto M, Kishi K, Hamazaki Y, Oikawa Y, Kawasaki T and Okamura A. Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusion Performed by Highly Experienced Japanese Specialists: The First Report From the Japanese CTO-PCI Expert Registry. *JACC Cardiovascular interventions*. 2017;10:2144-2154.

31. Ghoshhajra BB, Takx RAP, Stone LL, Girard EE, Brilakis ES, Lombardi WL, Yeh RW and Jaffer FA. Real-time fusion of coronary CT angiography with x-ray fluoroscopy during chronic total occlusion PCI. *European radiology*. 2017;27:2464-2473.

32. Karatasakis A, Danek BA, Karmpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel MP, Bahadorani JN, Wyman RM, Lombardi WL, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Moses JW, Kirtane AJ, Garcia S, Parikh MA, Ali ZA, Karacsonyi J, Kalra S, Rangan BV, Kalsaria P, Thompson CA, Banerjee S and Brilakis ES. Impact of Proximal Cap Ambiguity on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter US Registry. *J Invasive Cardiol*. 2016;28:391-396.

33. Vo MN, Karmpaliotis D and Brilakis ES. "Move the cap" technique for ambiguous or impenetrable proximal cap of coronary total occlusion. *Catheter Cardiovasc Interv*. 2016;87:742-8.

34. Harding SA, Wu EB, Lo S, Lim ST, Ge L, Chen JY, Quan J, Lee SW, Kao HL and Tsuchikane E. A New Algorithm for Crossing Chronic Total Occlusions From the Asia Pacific Chronic Total Occlusion Club. *JACC Cardiovascular interventions*. 2017;10:2135-2143.

35. Azzalini L, Carlino M, Brilakis ES, Vo M, Rinfret S, Uretsky BF, Karmpaliotis D and Colombo A. Subadventitial techniques for chronic total occlusion percutaneous coronary intervention: The concept of "vessel architecture". *Catheter Cardiovasc Interv*. 2018;91:725-734.

36. Galassi AR, Tomasello SD, Crea F, Costanzo L, Campisano MB, Marza F and Tamburino C. Transient impairment of vasomotion function after successful chronic total occlusion recanalization. *J Am Coll Cardiol*. 2012;59:711-8.

37. Sakakura K, Nakano M, Otsuka F, Yahagi K, Kutys R, Ladich E, Finn AV, Kolodgie FD and Virmani R. Comparison of pathology of chronic total occlusion with and without coronary artery bypass graft. *Eur Heart J*. 2014;35:1683-93.

38. McEntegart MB, Badar AA, Ahmad FA, Shaukat A, MacPherson M, Irving J, Strange J, Bagnall AJ, Hanratty CG, Walsh SJ, Werner GS and Spratt JC. The collateral circulation of coronary chronic total occlusions. *EuroIntervention*. 2016;11:e1596-603.

39. Huang CC, Lee CK, Meng SW, Hung CS, Chen YH, Lin MS, Yeh CF and Kao HL. Collateral Channel Size and Tortuosity Predict Retrograde Percutaneous Coronary Intervention Success for Chronic Total Occlusion. *Circ Cardiovasc Interv*. 2018;11:e005124.

40. Dautov R, Urena M, Nguyen CM, Gibrat C and Rinfret S. Safety and effectiveness of the surfing technique to cross septal collateral channels during retrograde chronic total occlusion percutaneous coronary intervention. *EuroIntervention*. 2017;12:e1859-e1867.

41. Rathore S, Katoh O, Matsuo H, Terashima M, Tanaka N, Kinoshita Y, Kimura M, Tsuchikane E, Nasu K, Ehara M, Asakura K, Asakura Y and Suzuki T. Retrograde percutaneous recanalization of chronic total occlusion of the coronary arteries: procedural outcomes and predictors of success in contemporary practice. *Circ Cardiovasc Interv*. 2009;2:124-32.

42. Benincasa S, Azzalini L, Carlino M, Bellini B, Giannini F, Zhao X and Colombo A. Outcomes of the retrograde approach through epicardial versus non-epicardial collaterals in chronic total occlusion percutaneous coronary intervention. *Cardiovasc Revasc Med*. 2017;18:393-398.

43. Christopoulos G, Wyman RM, Alaswad K, Karmpaliotis D, Lombardi W, Grantham JA, Yeh RW, Jaffer FA, Cipher DJ, Rangan BV, Christakopoulos GE, Kypreos MA, Lembo N, Kandzari D, Garcia S, Thompson CA, Banerjee S and Brilakis ES. Clinical Utility of the Japan-Chronic Total Occlusion Score in Coronary Chronic Total Occlusion Interventions: Results from a Multicenter Registry. *Circ Cardiovasc Interv*. 2015;8:e002171.

44. Azzalini L, Ojeda S, Karatasakis A, Maeremans J, Tanabe M, La Manna A, Dautov R, Ybarra LF, Benincasa S, Bellini B, Candilio L, Demir OM, Hidalgo F, Karacsonyi J, Gravina G, Micciche E, D'Agosta G, Venuti G, Tamburino C, Pan M, Carlino M, Dens J, Brilakis ES, Colombo A and Rinfret S. Long-Term Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusion in Patients Who Have Undergone Coronary Artery Bypass Grafting vs Those Who Have Not. *Can J Cardiol*. 2018;34:310-318.

45. Morino Y, Abe M, Morimoto T, Kimura T, Hayashi Y, Muramatsu T, Ochiai M, Noguchi Y, Kato K, Shibata Y, Hiasa Y, Doi O, Yamashita T, Hinohara T, Tanaka H and Mitsudo K. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: the J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. *JACC Cardiovascular interventions*. 2011;4:213-21.

46. Tanaka H, Morino Y, Abe M, Kimura T, Hayashi Y, Muramatsu T, Ochiai M, Noguchi Y, Kato K, Shibata Y, Hiasa Y, Doi O, Yamashita T, Morimoto T, Hinohara T, Fujii T and Mitsudo K. Impact of J-CTO score on procedural outcome and target lesion revascularisation after percutaneous coronary intervention for chronic total occlusion: a substudy of the J-CTO Registry (Multicentre CTO Registry in Japan). *EuroIntervention*. 2016;11:981-8.

47. Christopoulos G, Kandzari DE, Yeh RW, Jaffer FA, Karmpaliotis D, Wyman MR, Alaswad K, Lombardi W, Grantham JA, Moses J, Christakopoulos G, Tarar MN, Rangan BV, Lembo N, Garcia S, Cipher D, Thompson CA, Banerjee S and Brilakis ES. Development and Validation of a Novel Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions: The PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score. *JACC Cardiovascular interventions*. 2016;9:1-9.

48. Maeremans J, Spratt JC, Knaapen P, Walsh S, Agostoni P, Wilson W, Avran A, Faurie B, Bressollette E, Kayaert P, Bagnall AJ, Smith D, McEntegart MB, Smith WHT, Kelly P, Irving J, Smith EJ, Strange JW and Dens J. Towards a contemporary, comprehensive scoring system for determining technical outcomes of hybrid percutaneous chronic total occlusion treatment: The RECHARGE score. *Catheter Cardiovasc Interv*. 2018;91:192-202.

49. Alessandrino G, Chevalier B, Lefevre T, Sanguineti F, Garot P, Unterseeh T, Hovasse T, Morice MC and Louvard Y. A Clinical and Angiographic Scoring System to Predict the Probability of Successful First-Attempt Percutaneous Coronary Intervention in Patients With Total Chronic Coronary Occlusion. *JACC Cardiovascular interventions*. 2015;8:1540-8.

50. Galassi AR, Boukhris M, Azzarelli S, Castaing M, Marza F and Tomasello SD. Percutaneous Coronary Revascularization for Chronic Total Occlusions: A Novel Predictive Score of Technical Failure Using Advanced Technologies. *JACC Cardiovascular interventions*. 2016;9:911-22.

51. Ellis SG, Burke MN, Murad MB, Graham JJ, Badawi R, Toma C, Meltser H, Nair R, Buller C, Whitlow PL and Group C. Predictors of Successful Hybrid-Approach Chronic Total Coronary Artery Occlusion Stenting: An Improved Model With Novel Correlates. *JACC Cardiovascular interventions*. 2017;10:1089-1098.

52. Khanna R, Pandey CM, Bedi S, Ashfaq F and Goel PK. A weighted angiographic scoring model (W-CTO score) to predict success of antegrade wire crossing in chronic total occlusion: analysis from a single centre. *AsiaIntervention*. 2018;4:18-25.

53. Szijgyarto Z, Rampat R, Werner GS, Ho C, Reifart N, Lefevre T, Louvard Y, Avran A, Mashayekhi K, Buettner HJ, Di Mario C, Gershlick A, Escaned J, Sianos G, Galassi AR, Garbo R, Goktekin O, Meyer-Gessner M, Lauer B, Elhadad S, Bufe A, Boudou N, Sievert H, Martin-Yuste V, Thuesen L, Erglis A, Christiansen E, Spratt J, Bryniarski L, Clayton T and Hildick-Smith D. Derivation and validation of a chronic total coronary occlusion intervention procedural success score from the 20,000 patient EuroCTO registry: the EuroCTO (CASTLE) score. *JACC Cardiovascular interventions*. 2018:in press.

54. Opolski MP, Achenbach S, Schuhback A, Rolf A, Mollmann H, Nef H, Rixe J, Renker M, Witkowski A, Kepka C, Walther C, Schlundt C, Debski A, Jakubczyk M and Hamm CW. Coronary computed tomographic prediction rule for time-efficient guidewire crossing through chronic total occlusion: insights from the CT-RECTOR multicenter registry (Computed Tomography Registry of Chronic Total Occlusion Revascularization). *JACC Cardiovascular interventions*. 2015;8:257-67.

55. Yu CW, Lee HJ, Suh J, Lee NH, Park SM, Park TK, Yang JH, Song YB, Hahn JY, Choi SH, Gwon HC, Lee SH, Choe YH, Kim SM and Choi JH. Coronary Computed Tomography Angiography Predicts Guidewire Crossing and Success of Percutaneous Intervention for Chronic Total Occlusion: Korean Multicenter CTO CT Registry Score as a Tool for Assessing Difficulty in Chronic Total Occlusion Percutaneous Coronary Intervention. *Circ Cardiovasc Imaging*. 2017;10.

56. Karatasakis A, Danek BA, Karmpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel M, Bahadorani JN, Lombardi WL, Wyman RM, Grantham JA, Kandzari DE, Lembo NJ, Doing AH, Toma C, Moses JW, Kirtane AJ, Parikh MA, Ali ZA, Garcia S, Kalsaria P, Karacsonyi J, Alame AJ, Thompson CA, Banerjee S and Brilakis ES. Comparison of various scores for predicting success of chronic total occlusion percutaneous coronary intervention. *Int J Cardiol*. 2016;224:50-56.

57. Danek BA, Karatasakis A, Karmpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Patel MP, Mahmud E, Lombardi WL, Wyman MR, Grantham JA, Doing A, Kandzari DE, Lembo NJ, Garcia S, Toma C, Moses JW, Kirtane AJ, Parikh MA, Ali ZA, Karacsonyi J, Rangan BV, Thompson CA, Banerjee S and Brilakis ES. Development and Validation of a Scoring System for Predicting Periprocedural Complications During Percutaneous Coronary Interventions of Chronic Total Occlusions: The Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO) Complications Score. *J Am Heart Assoc*. 2016;5.

58. Azzalini L, Uretsky B, Brilakis ES, Colombo A and Carlino M. Contrast modulation in chronic total occlusion percutaneous coronary intervention. *Catheter Cardiovasc Interv*. 2018.

59. Tajti P, Karmpaliotis D, Alaswad K, Jaffer FA, Yeh RW, Patel M, Mahmud E, Choi JW, Burke MN, Doing AH, Dattilo P, Toma C, Smith AJC, Uretsky B, Holper E, Wyman RM, Kandzari DE, Garcia S, Krestyaninov O, Khelimskii D, Koutouzis M, Tsiafoutis I, Moses JW, Lembo NJ, Parikh M, Kirtane AJ, Ali ZA, Doshi D, Rangan BV, Ungi I, Banerjee S and Brilakis ES. The Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: Update From the PROGRESS CTO Registry. *JACC Cardiovascular interventions*. 2018;11:1325-1335.

60. Maeremans J, Walsh S, Knaapen P, Spratt JC, Avran A, Hanratty CG, Faurie B, Agostoni P, Bressollette E, Kayaert P, Bagnall AJ, Egred M, Smith D, Chase A, McEntegart MB, Smith WH, Harcombe A, Kelly P, Irving J, Smith EJ, Strange JW and Dens J. The Hybrid Algorithm for Treating Chronic Total Occlusions in Europe: The RECHARGE Registry. *J Am Coll Cardiol*. 2016;68:1958-1970.

61. Wilson WM, Walsh SJ, Yan AT, Hanratty CG, Bagnall AJ, Egred M, Smith E, Oldroyd KG, McEntegart M, Irving J, Strange J, Douglas H and Spratt JC. Hybrid approach improves success of chronic total occlusion angioplasty. *Heart*. 2016;102:1486-93.

62. Colombo A, Mikhail GW, Michev I, Iakovou I, Airoldi F, Chieffo A, Rogacka R, Carlino M, Montorfano M, Sangiorgi GM, Corvaja N and Stankovic G. Treating chronic total occlusions using subintimal tracking and reentry: the STAR technique. *Catheter Cardiovasc Interv*. 2005;64:407-11; discussion 412.

63. Valenti R, Vergara R, Migliorini A, Parodi G, Carrabba N, Cerisano G, Dovellini EV and Antoniucci D. Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. *J Am Coll Cardiol*. 2013;61:545-50.

64. Godino C, Latib A, Economou FI, Al-Lamee R, Ielasi A, Bassanelli G, Figini F, Chieffo A, Montorfano M, Colombo A and Carlino M. Coronary chronic total occlusions: mid-term comparison of clinical outcome following the use of the guided-STAR technique and conventional anterograde approaches. *Catheter Cardiovasc Interv*. 2012;79:20-7.

65. Hirai T, Grantham JA, Sapontis J, Cohen DJ, Marso SP, Lombardi W, Karmpaliotis D, Moses J, Nicholson WJ, Pershad A, Wyman RM, Spaedy A, Cook S, Doshi P, Federici R, Nugent K, Gosch KL, Spertus JA, Salisbury AC and Group OCS. Impact of subintimal plaque modification procedures on health status after unsuccessful chronic total occlusion angioplasty. *Catheter Cardiovasc Interv*. 2018;91:1035-1042.

66. Whitlow PL, Burke MN, Lombardi WL, Wyman RM, Moses JW, Brilakis ES, Heuser RR, Rihal CS, Lansky AJ, Thompson CA and Investigators FA-CT. Use of a novel crossing and re-entry system in coronary chronic total occlusions that have failed standard crossing techniques: results of the FAST-CTOs (Facilitated Antegrade Steering Technique in Chronic Total Occlusions) trial. *JACC Cardiovascular interventions*. 2012;5:393-401.

67. Karacsonyi J, Tajti P, Rangan BV, Halligan SC, Allen RH, Nicholson WJ, Harvey JE, Spaedy AJ, Jaffer FA, Grantham JA, Salisbury A, Hart AJ, Safley DM, Lombardi WL, Hira R, Don C, McCabe JM, Burke MN, Alaswad K, Koenig GC, Sanghvi KA, Ice D, Kovach RC, Varghese V, Murad B, Baran KW, Resendes E, Martinez-Parachini JR, Karatasakis A, Danek BA, Iwnetu R, Roesle M, Khalili H, Banerjee S and Brilakis ES. Randomized Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusions: The CrossBoss First Trial. *JACC Cardiovascular interventions*. 2018;11:225-233.

68. Galassi AR, Boukhris M, Tomasello SD, Marza F, Azzarelli S, Giubilato S and Khamis H. Long-term clinical and angiographic outcomes of the mini-STAR technique as a bailout strategy for percutaneous coronary intervention of chronic total occlusion. *Can J Cardiol*. 2014;30:1400-6.

69. Galassi AR, Tomasello SD, Costanzo L, Campisano MB, Barrano G, Ueno M, Tello-Montoliu A and Tamburino C. Mini-STAR as bail-out strategy for percutaneous coronary intervention of chronic total occlusion. *Catheter Cardiovasc Interv*. 2012;79:30-40.

70. Karatasakis A, Danek BA, Karacsonyi J, Azzalini L, Carlino M, Rinfret S, Vo M, Rangan BV, Burke MN, Banerjee S and Brilakis ES. Mid-term outcomes of chronic total occlusion percutaneous coronary intervention with subadventitial vs. intraplaque crossing: A systematic review and meta-analysis. *Int J Cardiol*. 2018;253:29-34.

71. Wilson WM, Walsh SJ, Bagnall A, Yan AT, Hanratty CG, Egred M, Smith E, Oldroyd KG, McEntegart M, Irving J, Douglas H, Strange J and Spratt JC. One-year outcomes after successful chronic total occlusion percutaneous coronary intervention: The impact of dissection re-entry techniques. *Catheter Cardiovasc Interv*. 2017;90:703-712.

72. Maeremans J, Dens J, Spratt JC, Bagnall AJ, Stuijfzand W, Nap A, Agostoni P, Wilson W, Hanratty CG, Wilson S, Faurie B, Avran A, Bressollette E, Egred M, Knaapen P, Walsh S and Investigators R. Antegrade Dissection and Reentry as Part of the Hybrid Chronic Total Occlusion Revascularization Strategy: A Subanalysis of the RECHARGE Registry (Registry of CrossBoss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom). *Circ Cardiovasc Interv*. 2017;10.

73. Azzalini L, Dautov R, Brilakis ES, Ojeda S, Benincasa S, Bellini B, Karatasakis A, Chavarria J, Rangan BV, Pan M, Carlino M, Colombo A and Rinfret S. Procedural and longer-term outcomes of wire- versus device-based antegrade dissection and re-entry techniques for the percutaneous revascularization of coronary chronic total occlusions. *Int J Cardiol*. 2017;231:78-83.

74. Danek BA, Karatasakis A, Karmpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Patel M, Bahadorani J, Lombardi WL, Wyman MR, Grantham JA, Doing A, Moses JW, Kirtane A, Parikh M, Ali ZA, Kalra S, Kandzari DE, Lembo N, Garcia S, Rangan BV, Thompson CA, Banerjee S and Brilakis ES. Use of antegrade dissection re-entry in coronary chronic total occlusion percutaneous coronary intervention in a contemporary multicenter registry. *Int J Cardiol*. 2016;214:428-37.

75. Joyal D, Thompson CA, Grantham JA, Buller CEH and Rinfret S. The Retrograde Technique for Recanalization of Chronic Total Occlusions: a Step-by-Step Approach. *JACC Cardiovascular interventions*. 2012;5:1-11.

76. Wu EB, Tsuchikane E, Lo S, Lim TS, Ge L, Che JY, Qian J, Lee SW, Harding S and Kao HL. Retrograde algorithm for chronic total occlusion from the Asia Pacific Chronic Total Occlusion club. *AsiaIntervention*. 2018;4:98-107.

77. Huang Z, Zhang B, Chai W, Ma D, Liao H, Zhong Z, Wang F and Lin J. Usefulness and Safety of a Novel Modification of the Retrograde Approach for the Long Tortuous Chronic Total Occlusion of Coronary Arteries. *Int Heart J*. 2017;58:351-356.

78. Brilakis ES, Grantham JA, Rinfret S, Wyman RM, Burke MN, Karmpaliotis D, Lembo N, Pershad A, Kandzari DE, Buller CE, Demartini T, Lombardi WL and Thompson CA. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. *JACC Cardiovascular interventions*. 2012;5:367-79.

79. Christopoulos G, Karmpaliotis D, Alaswad K, Yeh RW, Jaffer FA, Wyman RM, Lombardi WL, Menon RV, Grantham JA, Kandzari DE, Lembo N, Moses JW, Kirtane AJ, Parikh M, Green P, Finn M, Garcia S, Doing A, Patel M, Bahadorani J, Tarar MN, Christakopoulos GE, Thompson CA, Banerjee S and Brilakis ES. Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry. *Int J Cardiol*. 2015;198:222-228.

80. Galassi AR, Sianos G, Werner GS, Escaned J, Tomasello SD, Boukhris M, Castaing M, Buttner JH, Bufe A, Kalnins A, Spratt JC, Garbo R, Hildick-Smith D, Elhadad S, Gagnor A, Lauer B, Bryniarski L, Christiansen EH, Thuesen L, Meyer-Gessner M, Goktekin O, Carlino M, Louvard Y, Lefevre T, Lismanis A, Gelev VL, Serra A, Marza F, Di Mario C, Reifart N and Euro CTOC. Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry. *J Am Coll Cardiol*. 2015;65:2388-400.

81. Galassi AR, Sumitsuji S, Boukhris M, Brilakis ES, Di Mario C, Garbo R, Spratt JC, Christiansen EH, Gagnor A, Avran A, Sianos G and Werner GS. Utility of Intravascular Ultrasound in Percutaneous Revascularization of Chronic Total Occlusions: An Overview. *JACC Cardiovascular interventions*. 2016;9:1979-1991.

82. Brilakis ES, Banerjee S, Karmpaliotis D, Lombardi WL, Tsai TT, Shunk KA, Kennedy KF, Spertus JA, Holmes DR, Jr. and Grantham JA. Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: A Report From the NCDR (National Cardiovascular Data Registry). *JACC Cardiovascular interventions*. 2015;8:245-53.

83. Wu EB and Tsuchikane E. The inherent catastrophic traps in retrograde CTO PCI. *Catheter Cardiovasc Interv*. 2018;91:1101-1109.

84. Tajti P, Karatasakis A, Danek BA, Alaswad K, Karmpaliotis D, Jaffer FA, Choi JW, Yeh RW, Patel M, Mahmud E, Burke MN, Krestyaninov O, Khelimskii D, Toma C, Doing AH, Uretsky B, Koutouzis M, Tsiafoutis I, Wyman RM, Garcia S, Holper E, Xenogiannis I, Rangan BV, Banerjee S, Ungi I and Brilakis ES. In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. *J Invasive Cardiol*. 2018.

85. Habara M, Tsuchikane E, Muramatsu T, Kashima Y, Okamura A, Mutoh M, Yamane M, Oida A, Oikawa Y, Hasegawa K and Retrograde Summit I. Comparison of percutaneous coronary intervention for chronic total occlusion outcome according to operator experience from the Japanese retrograde summit registry. *Catheter Cardiovasc Interv*. 2016;87:1027-35.

86. Okamura A, Yamane M, Muto M, Matsubara T, Igarashi Y, Nakamura S, Muramatsu T, Fujita T, Oida A and Tsuchikane E. Complications during retrograde approach for chronic coronary total occlusion: Sub-analysis of Japanese multicenter registry. *Catheter Cardiovasc Interv*. 2016;88:7-14.

87. Kotsia AP, Brilakis ES and Karmpaliotis D. Thrombin injection for sealing epicardial collateral perforation during chronic total occlusion percutaneous coronary interventions. *J Invasive Cardiol*. 2014;26:E124-6.

88. Wilson WM, Spratt JC and Lombardi WL. Cardiovascular collapse post chronic total occlusion percutaneous coronary intervention due to a compressive left atrial hematoma managed with percutaneous drainage. *Catheter Cardiovasc Interv*. 2015;86:407-11.

89. Karatasakis A, Akhtar YN and Brilakis ES. Distal coronary perforation in patients with prior coronary artery bypass graft surgery: The importance of early treatment. *Cardiovasc Revasc Med*. 2016;17:412-7.

90. Kim BK, Shin DH, Hong MK, Park HS, Rha SW, Mintz GS, Kim JS, Kim JS, Lee SJ, Kim HY, Hong BK, Kang WC, Choi JH, Jang Y and Investigators C-IS. Clinical Impact of Intravascular Ultrasound-Guided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus Biolimus-Eluting Stent Implantation: Randomized Study. *Circ Cardiovasc Interv*. 2015;8:e002592.

91. Tian NL, Gami SK, Ye F, Zhang JJ, Liu ZZ, Lin S, Ge Z, Shan SJ, You W, Chen L, Zhang YJ, Mintz G and Chen SL. Angiographic and clinical comparisons of intravascular ultrasound- versus angiography-guided drug-eluting stent implantation for patients with chronic total occlusion lesions: two-year results from a randomised AIR-CTO study. *EuroIntervention*. 2015;10:1409-17.

92. Karacsonyi J, Alaswad K, Jaffer FA, Yeh RW, Patel M, Bahadorani J, Karatasakis A, Danek BA, Doing A, Grantham JA, Karmpaliotis D, Moses JW, Kirtane A, Parikh M, Ali Z, Lombardi WL, Kandzari DE, Lembo N, Garcia S, Wyman MR, Alame A, Nguyen-Trong PK, Resendes E, Kalsaria P, Rangan BV, Ungi I, Thompson CA, Banerjee S and Brilakis ES. Use of Intravascular Imaging During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. *J Am Heart Assoc*. 2016;5.

93. Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, Tian N, Lin S, Lu Q, Wu X, Li Q, Liu Z, Chen Y, Qian X, Juan W, Chai D, Chen C, Li X, Gogas BD, Pan T, Shan S, Ye F and Chen SL. Intravascular Ultrasound-Guided Versus Angiography-Guided Implantation of Drug-Eluting Stent in All-Comers: The ULTIMATE trial. *J Am Coll Cardiol*. 2018.

94. Zivelonghi C, Suttorp MJ, Teeuwen K, van Kuijk JP, van der Heyden JAS, Eefting FD, Rensing BJ, Ten Berg JM, van den Brink FS, Benfari G, Tijssen JGP, Ribichini F, Henriques JPS and Agostoni P. Clinical Implications of Distal Vessel Stenosis After Successful Coronary Chronic Total Occlusion Recanalization. *JACC Cardiovascular interventions*. 2018;11:2343-2345.

**Acknowledgement.** We would like to recognize the assistance of Dr. Iosif Xenogiannis in the creation of this document.

**Table 1**. Key principles on the indications and technique of chronic total occlusion percutaneous coronary intervention.

|  |  |
| --- | --- |
| 1 | The principal indication for CTO-PCI is to improve symptoms |
| 2 | Dual coronary angiography and thorough, structure angiographic review |
| 3 | Use of a microcatheter for guidewire support  |
| 4 | There are 4 CTO crossing strategies: antegrade wire escalation, antegrade dissection/re-entry, retrograde wire escalation, and retrograde dissection/re-entry |
| 5 | Change of equipment and technique increases the likelihood of success and improves the efficiency of the procedure |
| 6 | Centers and physicians performing CTO-PCI should have the necessary equipment, expertise and experience to optimize success and minimize and manage complications |
| 7 | Every effort should be made to optimize stent deployment in CTO PCI, including the frequent use of intravascular imaging |

**Table 2**. Contemporary series of chronic total occlusion percutaneous coronary intervention.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Authors** | **Acronym** | **Study Period** | **Centers** | **Cases** | **Technical Success** | **Procedural Success** | **Overall MACE** | **Death** | **Acute MI** | **Stroke** | **TVR** | **Tamponade** |
| **Habara et al. 85** | **Japanese Retrograde Summit Registry** | 2012–2013 | 56 | 3,229 | — | 88% | 0.5% | 0.2% | 0.1% | 0.1% | — | 0.3% |
| **Tajti et al. 59** | **PROGRESS-CTO** | 2012–2017 | 20 | 3,055 | 87% | 85% | 3.0% | 0.3% | 0.7% | 0.1% | 0.2% | 0.5% |
| **Suzuki et al. 30** | **Japanese CTO-PCI Expert Registry** | 2014–2015 | 41 | 2,846 | 90% | 89% | <2% | 0.2% | 1.2% | 0.2% | 0.2% | 0.4% |
| **Maeremans et al. 60** | **RECHARGE** | 2014–2015 | 17 | 1,253 | 89% | 86% | 2.6% | 0.2% | 0.2% | 2.2% | 0.1% | 1.3% |
| **Wilson et al. 61** | **UK Hybrid** | 2012–2014 | 7 | 1,156 | 90% | — | 1.6% | 0.0% | 0.8% | 0.4% | 0.0% | 0.7% |
| **Sapontis et al. 3** | **OPEN-CTO** | 2013–2017 | 12 | 1,000 | 86% | 85% | 7.0% | 0.9% | 2.6% | 0.0% | 0.1% | — |

The studies are listed according to patient enrollment.

PROGRESS-CTO: Prospective Global Registry for the Study of Chronic Total Occlusion Intervention

RECHARGE: REgistry of Crossboss and Hybrid procedures in FrAnce, the NetheRlands, BelGium and UnitEd Kingdom

UK hybrid: United Kingdom hybrid registry

OPEN CTO: Outcomes, Patient Health Status and Efficiency in Chronic Total Occlusion Hybrid Procedures

MACE, major adverse cardiac events; MI, myocardial infarction; TVR, target vessel revascularization.